Study Title: Phase 2 Trial With Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers: Big Ten Cancer Research Consortium BTCRC-BRE18-337
 

• Closed to Accrual at:
  • University of Illinois Cancer Center
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center
  • Holden Comprehensive Cancer Center, University of Iowa
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
  • University of Wisconsin Carbone Cancer Center
• Learn more:
  • clinicaltrials.gov: NCT03911973
  • Big Ten CRC News Release
• Publications and Presentations:
  • Poster: 2023 San Antonio Breast Cancer Symposium
  • Publication: 2022 ASCO Annual Meeting
  • Ongoing Trials Session: 2019 San Antonio Breast Cancer Symposium

Study Contact: studies@hoosiercancer.org; (317) 921-2050.